Overview

Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to obtain single dose safety and pharmacokinetic (PK) data of IDX184 in humans. No formal hypotheses are to be tested in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.